• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Outcomes of systemic sclerosis associated interstitial lung disease patients with a persistent inflammatory phenotype based on serial CRP measurements.

作者信息

Volkmann Elizabeth R, Tashkin Donald P

机构信息

Medicine, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, California, USA

Medicine, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, California, USA.

出版信息

Thorax. 2023 Dec;78(12):1166-1167. doi: 10.1136/thorax-2023-220820. Epub 2023 Oct 5.

DOI:10.1136/thorax-2023-220820
PMID:37798113
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11392430/
Abstract
摘要

相似文献

1
Outcomes of systemic sclerosis associated interstitial lung disease patients with a persistent inflammatory phenotype based on serial CRP measurements.基于连续C反应蛋白测量结果的系统性硬化症相关间质性肺病患者持续炎症表型的预后
Thorax. 2023 Dec;78(12):1166-1167. doi: 10.1136/thorax-2023-220820. Epub 2023 Oct 5.
2
Phenotyping by persistent inflammation in systemic sclerosis associated interstitial lung disease: a EUSTAR database analysis.基于系统性硬化症相关间质性肺病持续性炎症的表型分析：EUSTAR 数据库分析。
Thorax. 2023 Dec;78(12):1188-1196. doi: 10.1136/thorax-2023-220541. Epub 2023 Oct 5.
3
The hidden costs of living with systemic sclerosis-associated interstitial lung disease.
Respirology. 2022 Jul;27(7):486-487. doi: 10.1111/resp.14275. Epub 2022 May 10.
4
The Molecular Mechanisms of Systemic Sclerosis-Associated Lung Fibrosis.系统性硬皮病相关肺纤维化的分子机制。
Int J Mol Sci. 2023 Feb 3;24(3):2963. doi: 10.3390/ijms24032963.
5
Treatment of Systemic Sclerosis-related Interstitial Lung Disease: A Review of Existing and Emerging Therapies.系统性硬皮病相关间质性肺病的治疗：现有和新兴疗法的综述。
Ann Am Thorac Soc. 2016 Nov;13(11):2045-2056. doi: 10.1513/AnnalsATS.201606-426FR.
6
Assessment and management of scleroderma lung disease.硬皮病肺病的评估与管理
Curr Opin Rheumatol. 1999 Nov;11(6):508-13.
7
Interstitial lung disease in systemic sclerosis.系统性硬化症中的间质性肺疾病
Lung. 2007 Jul-Aug;185(4):211-20. doi: 10.1007/s00408-007-9012-3.
8
[Interstitial lung disease (ILD) in systemic sclerosis (SSc)].[系统性硬化症（SSc）中的间质性肺疾病（ILD）]
Reumatizam. 2010;57(2):105-8.
9
Chronic dyspnea with Raynaud's phenomenon and elevated ANA: A diagnosis of systemic sclerosis sine scleroderma.伴有雷诺现象和抗核抗体升高的慢性呼吸困难：无硬皮病的系统性硬化症诊断。
Am J Med Sci. 2023 Feb;365(2):198-204. doi: 10.1016/j.amjms.2022.01.023. Epub 2022 Mar 8.
10
Pulmonary physiology is poorly associated with radiological extent of disease in systemic sclerosis-associated interstitial lung disease.在系统性硬化症相关间质性肺疾病中，肺生理学与疾病的放射学范围关联不大。
Eur Respir J. 2019 May 2;53(5). doi: 10.1183/13993003.02182-2018. Print 2019 May.

引用本文的文献

1
Predictive role of inflammatory markers in characterizing the progression of interstitial lung disease: a retrospective analysis.炎症标志物在间质性肺疾病进展特征中的预测作用：一项回顾性分析
Am J Transl Res. 2025 May 15;17(5):3485-3495. doi: 10.62347/JZTW5621. eCollection 2025.

本文引用的文献

1
Safety and efficacy of rituximab in systemic sclerosis (DESIRES): a double-blind, investigator-initiated, randomised, placebo-controlled trial.利妥昔单抗治疗系统性硬化症的安全性和有效性（DESIRES）：一项由研究者发起的双盲、随机、安慰剂对照试验。
Lancet Rheumatol. 2021 Jul;3(7):e489-e497. doi: 10.1016/S2665-9913(21)00107-7. Epub 2021 May 26.
2
Phenotyping by persistent inflammation in systemic sclerosis associated interstitial lung disease: a EUSTAR database analysis.基于系统性硬化症相关间质性肺病持续性炎症的表型分析：EUSTAR 数据库分析。
Thorax. 2023 Dec;78(12):1188-1196. doi: 10.1136/thorax-2023-220541. Epub 2023 Oct 5.
3
Effect of nintedanib in patients with systemic sclerosis-associated interstitial lung disease and risk factors for rapid progression.尼达尼布治疗系统性硬皮病相关间质性肺病患者的效果及快速进展的危险因素。
RMD Open. 2023 Feb;9(1). doi: 10.1136/rmdopen-2022-002859.
4
Rituximab versus intravenous cyclophosphamide in patients with connective tissue disease-associated interstitial lung disease in the UK (RECITAL): a double-blind, double-dummy, randomised, controlled, phase 2b trial.利妥昔单抗与静脉注射环磷酰胺治疗英国结缔组织病相关间质性肺病患者（RECITAL）：一项双盲、双模拟、随机、对照、2b 期试验。
Lancet Respir Med. 2023 Jan;11(1):45-54. doi: 10.1016/S2213-2600(22)00359-9. Epub 2022 Nov 11.
5
Mediators of systemic sclerosis-associated interstitial lung disease (SSc-ILD): systematic review and meta-analyses.系统性硬化症相关间质性肺病（SSc-ILD）的介质：系统评价和荟萃分析。
Thorax. 2023 Aug;78(8):799-807. doi: 10.1136/thorax-2022-219226. Epub 2022 Oct 19.
6
Natural variability in the disease course of SSc-ILD: implications for treatment.系统性硬皮病相关间质性肺病病程中的自然变异性：对治疗的影响。
Eur Respir Rev. 2021 Mar 24;30(159). doi: 10.1183/16000617.0340-2020. Print 2021 Mar 31.
7
Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial.托西珠单抗治疗系统性硬化症：一项随机、双盲、安慰剂对照、3 期临床试验。
Lancet Respir Med. 2020 Oct;8(10):963-974. doi: 10.1016/S2213-2600(20)30318-0. Epub 2020 Aug 28.
8
The Reliability of Disease Activity Score in 28 Joints-C-Reactive Protein Might Be Overestimated in a Subgroup of Rheumatoid Arthritis Patients, When the Score Is Solely Based on Subjective Parameters: A Cross-sectional, Exploratory Study.当疾病活动评分仅基于主观参数时，28个关节疾病活动评分- C反应蛋白在类风湿关节炎患者亚组中的可靠性可能被高估：一项横断面探索性研究。
J Clin Rheumatol. 2017 Mar;23(2):102-106. doi: 10.1097/RHU.0000000000000469.
9
Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial.霉酚酸酯与口服环磷酰胺治疗硬皮病相关间质性肺病（SLS II）：一项随机对照、双盲、平行组试验。
Lancet Respir Med. 2016 Sep;4(9):708-719. doi: 10.1016/S2213-2600(16)30152-7. Epub 2016 Jul 25.
10
Measuring disease activity in adults with systemic lupus erythematosus: the challenges of administrative burden and responsiveness to patient concerns in clinical research.测量成年系统性红斑狼疮患者的疾病活动度：临床研究中管理负担和对患者关切问题的响应所面临的挑战。
Arthritis Res Ther. 2015 Jul 20;17(1):183. doi: 10.1186/s13075-015-0702-6.